Correlation Between Activated Clotting Time and Activated Partial Thromboplastin Time During Endovascular Treatment of Cerebral Aneurysms


Purpose: Endovascular treatment (EVT) of intracranial aneurysms (IA) requires a continuous anticoagulation to avoid thromboembolic complications. In order to monitor the anticoagulation, different tests may be used including the activated clotting time (ACT) and the activated partial thromboplastin time (APTT). The aim of this study was to compare ACT and APTT for the monitoring of the anticoagulation during EVT of IA. Methods: Patients referred for EVT of an IA were included. After induction, baseline ACT and APTT were recorded, followed by a bolus infusion of unfractionated heparin (50–1). The same tests were controlled five minutes later with the purpose of doubling the baseline ACT value. Correlation and agreement between both tests were evaluated for the percentage of change after the bolus. Multiple linear regressions were also calculated in order to show confounding factors. Complications and outcomes were also recorded. Results: 45 patients were checked for enrolment and 24 were included for analysis. Mean (SD) % variation for APTT was 432.1 (75.7) and 60.6 (23.0) for ACT with p < 0.0001. With the Bland-Altman method, value of Bias (SD) is 372 (86) with 95% limits of agreement range from 203 to 540. Pearson correlation for % variation shows r (95% CI) = –0.23 (–0.58 to 0.19) with p = 0.29 and R square = 0.05. 100% of the APTT values could be defined as excessive anticoagulation by opposition of the 8% obtained with ACT. Conclusions: This prospective observational study shows that ACT test is not well correlated with APTT and leads to a systematic excessive coagulation during EVT of IA.

Share and Cite:

D. Faraoni, B. Mine, W. Nabhan, P. Nokerman, Y. Deryck, M. Baurain and B. Lubicz, "Correlation Between Activated Clotting Time and Activated Partial Thromboplastin Time During Endovascular Treatment of Cerebral Aneurysms," Open Journal of Anesthesiology, Vol. 2 No. 1, 2012, pp. 1-6. doi: 10.4236/ojanes.2012.21001.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] M. J. Gounis, M. J. De Leo and A. K. Wakhloo, “Advances in Interventional Neuroradiology,” Stroke, Vol. 41, No. 2, 2010, e81-e87. doi:10.1161/STROKEAHA.109.574319
[2] Y. Fujii, S. Takeuchi, T. Koike, K. Nishimaki, Y. Ito, R. Tanaka and K. Okamoto, “Heparin Administration and Monitoring for Neuroangiography,” American Journal of Neuroradiology, Vol. 15, No. 1, 1994, pp. 51-54.
[3] A. Bandeira, G. Raphaeli, D. Baleriaux, M. Bruneau, O. De Witte and B. Lubicz, “Selective Embolization of Unruptured Intracranial Aneurysms is Associated with Low Retreatment Rate,” Neuroradiology, Vol. 52, No. 2, 2010, pp. 141-146. doi:10.1007/s00234-009-0607-7
[4] H. P. Grill, J. E. Spero and J. E. Granato, “Comparison of Activated Partial Thromboplastin Time to Activated Clotting Time for Adequacy of Heparin Anticoagulation Just before Percutaneous Transluminal Coronary Angioplas- ty,” American Journal of Cardiology, Vol. 71, No. 13, 1993, pp. 1219-1220. doi:10.1016/0002-9149(93)90649-W
[5] N. A. Guzzetta, H. G. Monitz, J. D. Fernandez, T. M. Fazlollah, A. Knezevic and B. E. Miller, “Correlations between Activated Clotting Time Values and Heparin Concentration Measurements in Young Infants Undergoing Cardiopulmonary Bypass,” Anesthesia and Analgesia, Vol. 111, No. 1, 2010, pp. 173-179.
[6] B. Tremey, B. Szekely, S. Schlumberger, D. Fran?ois, N. Liu, K. Sievert, M. Fischler, “Anticoagulation Monitoring During Vascular Surgery: Accuracy of the Hemochron Low Range Activated Clotting Time (ACT-LR),” British Journal of Anaesthesia, Vol. 96, No. 4, 2006, 453-459. doi:10.1093/bja/ael194
[7] R. Kubalek, A. Berlis, M. Schwab, J. Klisch, M. Schu- macher, “Activated Clotting Time or Activated Partial Thromboplastin Time as the Method of Choice for Patients Undergoing Neuroradiological Intervention,” Neuroradiology, Vol. 45, No. 5, 2003, 325-327.
[8] J. J. De Waele, S. Van Cauwenberghe, E. Hoste, D. Benoit, F. Colardyn, “The Use of the Activated Clotting Time for Monitoring Heparin Therapy in Critically Ill Patients,” Intensive Care Medicine, Vol. 29, No. 2, 2003, pp. 325-328.
[9] J. B. Bederson, E. S. Connolly Jr., H. H. Batjer, R. G. Dacey, J. E. Dion, M. N. Diringer, J. E. Duldner Jr, R. E. Harbaugh, A. B. Patel and R. H. Rosenwasser, “Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Statement for Healthcare Professionals from a Special Writing Group of the Stroke Council, American Heart Association,” Stroke, Vol. 40, No. 3, 2009, pp. 994-1025. doi:10.1161/STROKEAHA.108.191395
[10] M. D. Vergouwen, M. Vermeulen, B. A. Coert, E. S. Stroes and Y. B. Roos, “Microthrombosis after Aneurysmal Subarachnoid Hemorrhage: An Additional Explanation for Delayed Cerebral Ischemia,” Journal of Cerebral Blood Flow and Metabolism, Vol. 28, No. 11, 2008, pp. 1761- 1770. doi:10.1038/jcbfm.2008.74
[11] J. M. Simard, D. Schreibman, E. F. Aldrich, B. Stallmeyer, B. Le, R. F. James and N. Beaty, “Unfractionated Heparin: Multitargeted Therapy for Delayed Neurological Deficits Induced by Subarachnoid Hemorrhage,” Neurocritical Care, Vol. 13, No. 3, 2010, pp. 439-449. doi:10.1007/s12028-010-9435-1
[12] G. A. Schubert, C. Thome, M. Seiz, C. Douville and J. Eskridge, “Microembolic Signal Monitoring after Coiling of Unruptured Cerebral Aneurysms an Observational Analysis of 123 Cases,” American Journal of Neuroradiology, Vol. 32, No. 8, 2011, pp. 1386-1391.
[13] M. K. Varma, K. Price, V. Jayakrishnan, B. Manickam and G. Kessell, “Anaesthetic Considerations for Interventional Neuroradiology,” British Journal of Anaesthesia, Vol. 99, No. 1, 2007, pp. 75-85. doi:10.1093/bja/aem122
[14] S. Suzuki, A. Kurata, M. Yamada, K. Iwamoto, K. Nakahara, K. Sato, J. Niki, M. Sasaki, T. Kitahara, K. Fujii and S. Kan, “Outcomes Analysis of Ruptured Distal Anterior Cerebral Artery Aneurysms Treated by Endosaccular Em- bolization and Surgical Clipping,” Interventional Neuro- radiology, Vol. 17, No. 1, 2011, pp. 49-57.
[15] P. G. Hattersley, “Activated Coagulation Time of Whole Blood,” Journal of the American Medical Association, Vo. 196, No. 5, 1966, pp. 436-440. doi:10.1001/jama.1966.03100180108036
[16] J. D. Olson, C. F. Arkin, J. T. Brandt, M. T. Cunningham, A. Giles, J. A. Koepke, D. L. Witte, “College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Laboratory Monitoring of Unfractionated Heparin Therapy,” Archives of Pathology and Laboratory Medicine, Vol. 122, No. 9, 1998, pp. 782-798.
[17] M. T. Ganter, A. Monn, R. Tavakoli, R. Klaghofer, A. Zollinger and C. K. Hofer, “Kaolin-Based Activated Coagulation Time Measured by Sonoclot in Patients Undergoing Cardiopulmonary Bypass,” Journal of Cardiothoracic and Vascular Anesthesia, Vol. 21, No. 4, 2007, pp. 524- 528. doi:10.1053/j.jvca.2006.12.012
[18] A. I. O’Neill, C. McAllister, C. F. Corke and J. D. Parkin, “A Comparison of Five Devices for the Bedside Monitoring of Heparin Therapy,” Anaesthesia and Intensive Care Journal, Vol. 19, No. 4, 1991, pp. 592-596.
[19] L. Racioppi, A. Quinart, M. Biais, K. Nouette-Gaulain, P. Revel and F. Sztark, “Validation of a Bedside Activated Clotting Time Test (Hemochron Jr II Signature) with Low Dose Heparin Therapy,” Anaesthesia, Vol. 64, No. 4, 2009, pp. 430-434.
[20] A. Cuker, B. Ptashkin, B. A. Konkle, S. W. Pipe, H. C. Whinna, X. L. Zheng, D. B. Cines and E. S. Pollak, “Interlaboratory Agreement in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time,” Journal of Thrombosis and Haemostasis, Vol. 7, No. 1, 2009, pp. 80-86. doi:10.1111/j.1538-7836.2008.03224.x
[21] D. Bischof, “Thrombelastography in the Surgical Patient,” Minerva Anestesiologica, Vol. 76, No. 2, 2010, pp. 131- 137.
[22] K. Ruzicka, S. Kapiotis, P. Quehenberger, S. Handler, S. Hornykewycz, A. Michitsch, K. Huber, D. Clemens, M. Susan, I. Pabinger, S. Eichinger, B. Jilma and W. Speiser, “Evaluation of Bedside Prothrombin Time and Activated Partial Thromboplastin Time Measurement by Coagulation Analyzer CoaguCheck Plus in Various Clinical Settings,” Thrombosis Research, Vol. 87, No. 5, 1997, pp. 431-440. doi:10.1016/S0049-3848(97)00159-X
[23] M. Ferring, G. Reber, P. de Moerloose, P. Merlani, M. Diby, B. Ricou, “Point of Care and Central Laboratory Determinations of the aPTT Are not Interchangeable in Surgical Intensive Care Patients,” Canadian Journal of Anaesthesia, Vol. 48, No. 11, 2001, pp. 1155-1160. doi:10.1007/BF03020384

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.